Oncimmune Limited

Based in the UK, Oncimmune Limited Plc operates as a business subsidiary of Oncimmune Holdings that primarily focuses on advancing the early detection of cancer, including the CEmarked IVD EarlyCDT® Lung blood test, antibody platform and research and development pipeline. In May 2023, Freenome Holdings, Inc. a portfolio company of Agent Capital, Allen & Company, AME Cloud Ventures, Andreessen Horowitz, ArrowMark Partners, ARTIS Ventures, Asset Management Ventures, Bain Capital, BrightEdge Ventures, Byers Capital, Catalio Capital Management, Colorectal Cancer Alliance, CRV, Data Collective, EcoR1 Capital, Eventide Asset Management, Farallon Capital Management, Fidelity Investments, Founders Fund, HBM Partners, Innovation Endeavors, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente Ventures, Logos Capital, Novartis Venture Fund, Perceptive Advisors, Polaris Partners, Pura Vida Investments, RA Capital, Ridgeback Asset Management, Roche Venture Fund, S28 Capital, Sands Capital Ventures, Section 32, Soleus Capital Management, Suvretta Capital Management, T. Rowe Price Associates, Third Kind Venture Capital, and Verily Life Sciences LLC acquired Oncimmune Limited for GBP 13 million.

The flagship product of Oncimmune Limited was EarlyCDT® Lung, an in-vitro diagnostic blood test designed for early detection of lung cancer. The company also developed an antibody platform and maintained a research pipeline targeting various cancer indications. These technologies aimed to identify disease-associated autoantibodies, enabling earlier diagnosis and improved treatment strategies.